Literature DB >> 12209093

Polyclonal and allergen-induced cytokine responses in adults with asthma: resolution of asthma is associated with normalization of IFN-gamma responses.

Joanne M Smart1, Elisabeth Horak, Andrew S Kemp, Colin F Robertson, Mimi L K Tang.   

Abstract

BACKGROUND: Atopic disease is associated with skewing of immune responses away from a T(H)1 toward a T(H)2 profile. Previous studies have implicated this cytokine imbalance in the development of disease. However, it is not known whether normalization of this imbalance is conversely associated with disease resolution.
OBJECTIVE: To further delineate the role of reduced T(H)1 and increased T(H)2 cytokine production in the pathogenesis of atopic disease and to determine whether disease resolution is associated with alteration of cytokine profiles, we investigated cytokine responses in a cohort of adult patients with asthma followed from childhood.
METHODS: A cohort of wheezy children and control subjects aged 7 to 10 years were recruited from 1964 to 1967. Subjects were reevaluated every 7 years to monitor the outcome of childhood asthma. At the 42-year follow-up, 89 subjects from this cohort were evaluated for mitogen and house dust mite (HDM)-induced T(H)1 (IFN-gamma) and T(H)2 (IL-4, IL-5, and IL-13) cytokine responses. Cytokine responses were compared in patients with ongoing asthma, patients with resolved asthma, and control subjects.
RESULTS: Patients with severe ongoing asthma had significantly reduced HDM-induced IFN-gamma production compared with that of control subjects and patients with resolved asthma. In contrast, HDM-induced IFN-gamma production in patients with resolved asthma was equivalent to that seen in control subjects. Patients with ongoing and resolved asthma produced significantly higher levels of IL-5 in response to HDM compared with that seen in control subjects, with levels being equivalent in patients with active and resolved asthma. HDM-induced IL-13 production was significantly increased in the patients with resolved asthma when compared with that seen in the control subjects. PHA-induced cytokine responses did not parallel HDM-induced responses.
CONCLUSION: Patients with persistent and severe atopic asthma have a reduced HDM-induced T(H)1 response, whereas those with resolved asthma do not. This suggests that reduced HDM-induced IFN-gamma production might be an important factor contributing to ongoing severe asthma and that normalization of allergen-induced T(H)1 responses might be important for disease resolution. The finding that all subjects with a history of asthma displayed increased HDM-induced T(H)2 (IL-5 and IL-13) cytokine responses, irrespective of the presence or absence of asthma, suggests that increased T(H)2 responses reflect the presence of the atopic state per se rather than being specifically linked to asthma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209093     DOI: 10.1067/mai.2002.127283

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  21 in total

1.  Elevated allergen-induced IL-13 secretion predicts IgE elevation in children ages 2-5 years.

Authors:  N P Ly; Y Li; D L Sredl; D L Perkins; P W Finn; S T Weiss; D R Gold
Journal:  J Clin Immunol       Date:  2005-07       Impact factor: 8.317

Review 2.  Cytokine and anti-cytokine therapy for asthma.

Authors:  Hans-Uwe Simon
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

3.  Analysis of Th1/Th2 response pattern for erythrodermic psoriasis.

Authors:  Ping Zhang; Hong-Xiang Chen; Yi-Qun Duan; Wei-Zhen Wang; Tian-Zhu Zhang; Jia-Wen Li; Ya-Ting Tu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-08-19

4.  Novel Toll-Like Receptor 9 Agonist Derived from Cryptococcus neoformans Attenuates Allergic Inflammation Leading to Asthma Onset in Mice.

Authors:  Kaori Dobashi-Okuyama; Kazuyoshi Kawakami; Tomomitsu Miyasaka; Ko Sato; Keiko Ishii; Kaori Kawakami; Chiaki Masuda; Syugo Suzuki; Jun Kasamatsu; Hideki Yamamoto; Daiki Tanno; Emi Kanno; Hiromasa Tanno; Tasuku Kawano; Motoaki Takayanagi; Tomoko Takahashi; Isao Ohno
Journal:  Int Arch Allergy Immunol       Date:  2020-06-25       Impact factor: 2.749

5.  Differentiating asthma phenotypes in young adults through polyclonal cytokine profiles.

Authors:  Edward Zoratti; Suzanne Havstad; Ganesa Wegienka; Charlotte Nicholas; Kevin R Bobbitt; Kimberley J Woodcroft; Dennis R Ownby; Christine Cole Johnson
Journal:  Ann Allergy Asthma Immunol       Date:  2014-05-05       Impact factor: 6.347

Review 6.  The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both?

Authors:  Sergio Romagnani
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

7.  IFNG rs1861494 polymorphism is associated with IBD disease severity and functional changes in both IFNG methylation and protein secretion.

Authors:  Rivkah Gonsky; Richard L Deem; Carol J Landers; Talin Haritunians; Shaohong Yang; Stephan R Targan
Journal:  Inflamm Bowel Dis       Date:  2014-10       Impact factor: 5.325

8.  DNA methylation and the expression of IL-4 and IFN-gamma promoter genes in patients with bronchial asthma.

Authors:  Nam-Hee Kwon; Jin-Seuk Kim; Jin-Young Lee; Mi-Jung Oh; Dong-Chull Choi
Journal:  J Clin Immunol       Date:  2007-11-14       Impact factor: 8.317

9.  Local and systemic immunological parameters associated with remission of asthma symptoms in children.

Authors:  Susan Waserman; Parameswaran Nair; Denis Snider; Mary Conway; Lata Jayaram; Lynn M McCleary; Jerry Dolovich; Frederick E Hargreave; Jean S Marshall
Journal:  Allergy Asthma Clin Immunol       Date:  2012-10-08       Impact factor: 3.406

10.  Clinical efficacy and laboratory improvement of bacillus calmette-guerin vaccination on adult atopic asthma: a cohort study.

Authors:  Eulis A Datau; H Mewengkang; J C Matheos; I Purnawan; M Wibisono; K Wongdjaja; C Wibowo; E Surachmanto; F P Salim
Journal:  World Allergy Organ J       Date:  2008-04       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.